SPPI earnings

Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio's Omni-Channel Digital Sales Capabilities and ROLVEDON In-Person Commercial Team to Enhance Market Access and Growth across All Products Transaction Expected to Be Accretive to Assertio's Adjusted EPS and Operating Cash Flow in 2024 Spectrum Stockholders Will Receive Upfront Consideration of 0.1783 ASRT shares per SPPI Share ($1.14 per share) Plus One CVR for Total Potential Consideration of up to $1.34 per Share Upfront Consideration Represents a Premium of 65% and the Total Potential Consideration Repres

-- First launch quarter for ROLVEDON™ (eflapegrastim-xnst) injection -- -- Q4 and full year net sales of $10.1 million -- -- Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT -- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2022. Fourth Quarter 2022 and Recent Business Update First launch quarter for ROLVEDON, with net sales for the quarter and year ended December 31, 2022, totaling $10.1 million. Operating expenses decreased 45% year-over-year as the Company streamlined operation

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a corporate update on Wednesday, March 22, 2023, at 8:30 a.m. Eastern/5:30 a.m. Pacific. Conference Call and Webcast: Wednesday, March 22, 2023 @ 8:30 a.m. Eastern/5:30 a.m. Pacific To access the live call by phone, please go to this link (registration link) , and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A live web

-- ROLVEDON™ (eflapegrastim-xnst) injection is now commercially available -- -- Cash runway expected to extend through 2024 -- -- Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT -- Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended September 30, 2022 and provided a corporate update. Third Quarter 2022 and Recent Business Update Launched ROLVEDON™ (eflapegrastim-xnst) injection for adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant inci

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022, at 4:30 p.m. Eastern/1:30 p.m. Pacific. Conference Call and Webcast: Thursday, November 10, 2022 @ 4:30 p.m. Eastern/1:30 p.m. Pacific To access the live call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A live webcast of the

Eflapegrastim BLA under FDA review; PDUFA date September 9, 2022 FDA completes re-inspection of drug substance manufacturing facility for eflapegrastim Poziotinib NDA under FDA review with ODAC meeting on September 22, 2022 Management to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended June 30, 2022 and provided a corporate update. "The completion of the FDA re-inspection of the drug substance facility for eflapegrastim is a critical step in the regulatory review process. With

Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2022 financial results and provide a corporate update on Thursday, August 11, 2022 at 8:30 a.m. Eastern/5:30 a.m. Pacific. Conference Call and Webcast: Thursday, August 11, 2022 @ 8:30 a.m. Eastern/5:30 a.m. Pacific To access the live call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A live webcast of the call will

Resubmitted eflapegrastim BLA accepted for review by the FDA, PDUFA date September 9, 2022 Poziotinib NDA under review by FDA with PDUFA date of November 24, 2022 and will be discussed at ODAC meeting in September Positive poziotinib results in treatment naïve patients with NSCLC harboring HER2 exon 20 insertion mutations Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2022 and provided a corporate update. "We anticipate FDA approvals later this year fo

Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2022 financial results and provide a corporate update on Thursday, May 12, 2022 at 4:30 p.m. Eastern/1:30 p.m. Pacific. Conference Call and Webcast: Thursday, May 12, 2022 @ 4:30 p.m. Eastern/1:30 p.m. Pacific Domestic: (877) 837-3910 International: (973) 796-5077 Conference ID#: 2863606 The conference call will also be available from the Investor Relations section of the company's website at http://investor.sppirx.com/events-and-presentations and will be archived there shortly after the live eve

Eflapegrastim BLA resubmitted to FDA Poziotinib NDA accepted for FDA review in previously treated patients with NSCLC harboring HER2 exon 20 insertion mutations, PDUFA date November 24, 2022 Positive poziotinib results in treatment naïve patients with NSCLC harboring HER2 exon 20 insertion mutations Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period and full year ended December 31, 2021. "We have made significant progress against our core business objectives including the

Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2021 financial results and provide a corporate update on Thursday, March 17, 2022 at 4:30 p.m. Eastern/1:30 p.m. Pacific. Conference Call and Webcast: Thursday, March 17, 2022 @ 4:30 p.m. Eastern/1:30 p.m. Pacific Domestic: (877) 837-3910, Conference ID# 4573715 International: (973) 796-5077, Conference ID# 4573715 The conference call will also be available from the Investor Relations section of the company's website at http://investor.sppirx.com/events-and-presentations and will b

Poziotinib NDA is on track for submission in 2021 under a Fast Track designation Positive front line poziotinib data presented at ESMO Congress 2021 from Cohort 4 of the ZENITH20 clinical trial Preclinical data presented at 2021 AACR-NCI-EORTC (Triple) conference demonstrated the synergistic impact of poziotinib when combined with KRAS inhibitors in KRASG12C mutant specific cell line ROLONTIS® (eflapegrastim) CRL manufacturing deficiencies expected to be remediated by the end of the year Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology ther

Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2021 financial results and provide a corporate update on Wednesday, November 10, 2021 at 4:30 p.m. Eastern/1:30 p.m. Pacific. Conference Call and Webcast: Wednesday, November 10, 2021 @ 4:30 p.m. Eastern/1:30 p.m. Pacific   Domestic: (877) 837-3910, Conference ID# 6579214   International: (973) 796-5077, Conference ID# 6579214 The conference call will also be available from the Investor Relations section of the company's website at http://investor.sppirx.com/events-and-presentations an

Submission of poziotinib NDA on track for later in 2021 under a Fast Track designation The company is requesting a meeting with the FDA to clarify the remediation timelines regarding the Complete Response Letter (CRL) for ROLONTIS® (eflapegrastim) Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced financial results for the three-month period ended June 30, 2021 and provided a corporate update. "Momentum continues to build with poziotinib and the submission of the NDA later this year is our top corporate priority," sa

Spectrum Pharmaceuticals (NASDAQ:SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2021 financial results and provide a corporate update on Thursday, August 12, 2021 at 4:30 p.m. Eastern/1:30 p.m. Pacific. Conference Call and Webcast: Thursday, August 12, 2021 @ 4:30 p.m. Eastern/1:30 p.m. Pacific Domestic: (877) 837-3910, Conference ID# 2398834 International: (973) 796-5077, Conference ID# 2398834 The conference call will also be available from the Investor Relations section of the company's website at http://investor.sppirx.com/events-and-presentations and will be archived t